RNAC vs RNTX

Cartesian Therapeutics, Inc. vs Rein Therapeutics, Inc. — Valuation Comparison 2026

RNAC

Biotechnology
Cartesian Therapeutics, Inc.
Quality
4.4
out of 10
Value Trap
39
LOW
Price
$7.21
Last close
Models
7/13
Active
VS

RNTX

Biotechnology
Rein Therapeutics, Inc.
Quality
3.6
out of 10
Value Trap
37
LOW
Price
$1.11
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType RNAC Fair ValueRNAC Upside RNTX Fair ValueRNTX Upside
Bayesian DCF Intrinsic $5.09 -28.0% $0.03 -97.2%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $0.32 -69.0%
PWERM Option-Based $10.81 +49.9% $0.70 -36.8%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for RNAC vs RNTX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

RNAC vs RNTX — Which Stock Is More Undervalued?

RNAC scores higher with a 4.4/10 quality rating vs RNTX's 3.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Cartesian Therapeutics, Inc. (RNAC) and Rein Therapeutics, Inc. (RNTX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

RNAC currently trades at $7.21 with a QOC of 4.4/10, while RNTX trades at $1.11 with a QOC of 3.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).